• SIGN IN
  • GET HELP
  •  

    Home Study Details


    Program Type

    Home Study

    Credits

    1 Contact Hour(s)

    Release Date

    Friday, March 22, 2019

    Offline Date

    Tuesday, September 21, 2021

    ACPE Expiration Date

    Tuesday, March 22, 2022

    Target Audience

    Pharmacist, Pharmacy Technician, Nurse

    Cost

    $4.00

    • Overview

      As many as 1 in 200 hospitalized children may experience a thromboembolic event. Since there are no FDA approved parenteral anticoagulant therapies for the pediatric population,  pharmacists may be unfamiliar or uncomfortable with the treatment options. This program will educate pharmacists, nurses, and pharmacy technicians on the direct thrombin inhibitors, argatroban and bivalirudin, as alternatives to heparin for the treatment of pediatric thromboembolism. It will cover the challenges of heparin use in pediatrics as well as the advantages, disadvantages, dosing and monitoring of bivalirudin and argatroban. 

      Handouts

      • Homestudy PDF :   19066H01.pdf

      Financial Support By

      PharmCon
    • Pharmacist

      Identify the challenges associated with the use of heparin in pediatric patients.
      Describe dosing and monitoring of argatroban in pediatric patients, based on a dose finding, safety and efficacy study in pediatric patients.
      Describe dosing and monitoring of bivalirudin in pediatric patients, based on two dose-finding, safety and efficacy studies in pediatric patients.
      Describe the advantages and disadvantages of the use of direct thrombin inhibitors in pediatric patients.

      Pharmacy Technician

      Describe the advantages and disadvantages of the use of direct thrombin inhibitors in pediatric patients.
      Identify the challenges associated with the use of heparin in pediatric patients.
      Recognize dosing and monitoring of argatroban in pediatric patients, based on a dose finding, safety and efficacy study in pediatric patients.
      Recognize dosing and monitoring of bivalirudin in pediatric patients, based on two dose-finding, safety and efficacy studies in pediatric patients.

      Nurse

      Describe dosing and monitoring of bivalirudin in pediatric patients, based on two dose-finding, safety and efficacy studies in pediatric patients.
      Identify the challenges associated with the use of heparin in pediatric patients.
      Describe the advantages and disadvantages of the use of direct thrombin inhibitors in pediatric patients.
      Describe dosing and monitoring of argatroban in pediatric patients, based on a dose finding, safety and efficacy study in pediatric patients.
    • Activity Type

      Knowledge

      CE Broker

      20-652589

      Universal Activity Number

      Pharmacist 0798-0000-19-066-H01-P
      Pharmacy Technician 0798-0000-19-066-H01-T
      Nurse 0798-0000-19-066-H01-N

      ACPE PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      PharmCon is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

      In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.


    HARDWARE REQUIREMENTS
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
     
     


    SOFTWARE REQUIREMENTS
    Microsoft Edge
    Internet Explorer 8.0 or higher
    Google Chrome
    Safari
    Firefox 3.0.3 or higher
    Adobe Acrobat Reader


    NETWORK REQUIREMENTS
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
     
     
     

    This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).